MRL Ventures, GV, AbbVie Ventures, Lilly Asia Ventures and Amgen Ventures are all in line to exit the immuno-neurology drug developer.

Alector, a US-based immunotherapy developer backed by corporate investors Alphabet, AbbVie, Eli Lilly, Amgen and Merck & Co, filed on Monday for a $150m initial public offering. Founded in 2013, Alector is working on immuno-neurology therapies that will treat degenerative brain disorders by addressing dysfunction in the immune system. Part of the IPO proceeds will…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.